Eli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing
Eli Lilly (LLY) concluded the recent trading session at $531.46, signifying a +1.19% move from its prior day's close.
Lilly (LLY) to Buy POINT Biopharma, Strengthen Cancer Portfolio
Eli Lilly's (LLY) acquisition of POINT Biopharma, if successfully closed, is likely to bolster its portfolio of cancer drugs.
Eli Lilly exec behind diabetes blockbuster set retire
Mike Mason, the executive vice president and president of Lilly Diabetes & Obesity at Eli Lilly and Co (NYSE:LLY), is set to retire at the end of this year after a 34-year tenure with the pharmaceu...
Eli Lilly's head of diabetes and obesity unit to retire
Eli Lilly and Co said on Wednesday that the head of its diabetes and obesity division, Mike Mason, will retire by the end of the year after more than three decades with the drugmaker.
Why Eli Lilly Stock Was Looking Sickly Today
The pharmaceutical giant signed a deal to acquire cancer therapy developer Biopharma Global. Its asset-to-be is a developer of precision cancer therapies.
Eli Lilly Buys POINT Biopharma to Boost Its Cancer-Fighting Therapies
Shares of POINT Biopharma Global (PNT) skyrocketed over 80% in early trading on Tuesday after Eli Lilly (LLY) agreed to buy the radiopharmaceutical firm for $1.4 billion to expand its cancer-fighti...
Eli Lilly Stock Cools Despite Big Cancer Investment
Eli Lilly And Co (NYSE: LLY ) stock is down 2.5% to trade at $525.97 at last check, after the pharma company announced the acquisition of Point Biopharma Global (PNT) for $1.4 billion in an all-ca...
Eli Lilly Acquiring Cancer Therapy Developer For $1.4 Billion—A Nearly 90% Premium
American pharmaceutical company Eli Lilly plans to acquire cancer therapy firm Point Biopharma Global, the companies announced Tuesday, an expansion that comes as manu
Lilly's (LLY) Eczema Candidate Lebrikizumab Faces FDA Rejection
Lilly (LLY) gets a CRL for the eczema candidate, lebrikizumab, based on inspection findings at a third-party manufacturer.
Eli Lilly to Buy Point Biopharma for $1.4 Billion
Eli Lilly will acquire radiopharmaceutical company Point Biopharma Global for $12.50 a share.
Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion
Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.
Point Biopharma Global's stock jumps more than 80% after Lilly merger deal
Point Biopharma Global, Inc.'s PNT, +0.22% stock was up 83.4% in premarket trading on Tuesday after Eli Lilly & Co. LLY, +0.22% said it will pay $12.50 a share to acquire the Indianapolis-based can...
Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns
Biotech stocks have had a rough post-pandemic. In a year where the S&P500 is up more than 10% year to date, the biotech sector is still negative to flat.
Eli Lilly gets FDA complete response letter for skin treatment after inspection of third-party facility
Eli Lilly & Co. said Monday the U.S. Food and Drug Administration has issued a complete response letter for its lebrikizumab, a treatment for moderate-to-severe atopic dermatitis, after an inspecti...
U.S. FDA declines to approve Eli Lilly's skin disease drug
The U.S. Food and Drug Administration has declined to approve Eli Lilly's drug to treat a type of skin disease due to certain findings during an inspection of a contract manufacturer, the company s...
Related Companies